A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential (intravenous/oral) moxifloxacin 400 mg once daily to intravenous piperacillin/tazobactam 4.0/0.5 g every 8 hours follow
Read time: 1 mins
Last updated:25th Feb 2008
The objective of this study is to compare the efficacy and safety of two sequential (IV/PO) treatment regimens for the treatment of adult subjects with cSSSIs: Moxifloxacin, 400 mg IV every 24 hours followed by moxifloxacin 400 mg PO every 24 hours, and Piperacillin/tazobactam, 4.0/0.5 g administered IV three times daily followed by oral amoxicillin/clavulanic acid tablets, 875/125 mg twice daily.
|Study start date||2008-02-25|